Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study
Recruiting · NCT06093022 · Observational (researchers observe without assigning treatment) · Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
View the official record on ClinicalTrials.gov →What this trial is about
The liver represents the third most common site of breast cancer (BC) metastases behind the lymphatics and bone. The primary treatment for BCLM remains chemo-therapy and, more recently, targeted immunotherapy. The role of liver resection in BCLM remains controversial. The primary aim of the study is to compare the efficacy of liver resection vs. medical therapy alone in Breast Cancer Liver Metastasis (BCLM) patients.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- \> 18 years old
- BCLM
- BCLM and extra-hepatic disease
- Any treatment
- Ability to understand and sign the informed consent
Exclusion criteria
- Inability to provide the informed consent
- Patient who underwent Best Supportive Care or Palliation
Where it is running
1 location listed.
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome, Lazio, Italy